RecallRadar

FDA Device recall Z-1040-2017

AutoMate 2500 Family Catalog No. ODL25120 AutoMate 1200, ODL25125, AutoMate 1250, ODL25250 AutoMate 2500, ODL25255 Automate 2550

On 2017-01-25 the FDA classified a Class III recall of AutoMate 2500 Family Catalog No. ODL25120 AutoMate 1200, ODL25125, AutoMate 1250, ODL25250 AutoMate 2500, ODL25255 Automate 2550 by Beckman Coulter, citing beckman Coulter initiated a design change to update the Automate PC image to accommodate the operating system change to Windows 10.

Read the official FDA Device notice

AgencyFDA Device
Recall numberZ-1040-2017
ClassificationClass III
Statusterminated
Initiated2016-12-21
Published2017-01-25
Last updated2026-09-13 11:54 UTC
CompanyBeckman Coulter
DistributionMD

Product

AutoMate 2500 Family Catalog No. ODL25120 AutoMate 1200, ODL25125, AutoMate 1250, ODL25250 AutoMate 2500, ODL25255 Automate 2550. AutoMate 1200/1250/2500/2550 System Series is a semi-open, pre- and post-analytical sample processing and sorting system. The base system automates the sample sorting, decapping, and archiving process. Handling and sorting of samples includes automatic detection of the tube type and cap type (color). Optional features include an Aliquot Module for creation of labeled secondary tubes (including detection of the presence of adequate volume for the requested aliquots) and a Recapper Module to re-seal previously decapped tubes prior to archiving.

Reason

Beckman Coulter initiated a design change to update the Automate PC image to accommodate the operating system change to Windows 10.

Identifiers

code_infoODL25255-4437 ODL25255-4443 ODL25255-4444 ODL25255-4438

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:54 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-1040-2017%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.